Should the diverse biologic activity of effective antitumor agents be considered a hindrance to their clinical use?
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002273:Carcinogens; D002869:Chromosome Aberrations; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009603:Nitroso Compounds / Q000009:adverse effects; D009607:Nitrosourea Compounds / Q000009:adverse effects; D051381:Rats
D000970:Antineoplastic Agents; D002273:Carcinogens; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds